Relay Therapeutics, Inc. (RLAY)
- Previous Close
6.51 - Open
6.55 - Bid 6.30 x 1000
- Ask 6.34 x 500
- Day's Range
6.29 - 6.65 - 52 Week Range
5.70 - 13.32 - Volume
897,525 - Avg. Volume
1,236,048 - Market Cap (intraday)
837.602M - Beta (5Y Monthly) 1.68
- PE Ratio (TTM)
-- - EPS (TTM)
-2.63 - Earnings Date Aug 6, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.96
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
www.relaytx.comRecent News: RLAY
Performance Overview: RLAY
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RLAY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RLAY
Valuation Measures
Market Cap
837.60M
Enterprise Value
140.30M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
22.32
Price/Book (mrq)
1.12
Enterprise Value/Revenue
3.97
Enterprise Value/EBITDA
-0.80
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.58%
Return on Equity (ttm)
-40.40%
Revenue (ttm)
35.33M
Net Income Avi to Common (ttm)
-329.12M
Diluted EPS (ttm)
-2.63
Balance Sheet and Cash Flow
Total Cash (mrq)
749.61M
Total Debt/Equity (mrq)
7.01%
Levered Free Cash Flow (ttm)
-171.66M
Research Analysis: RLAY
Company Insights: RLAY
RLAY does not have Company Insights